• +1-646-491-9876
    • +91-20-67278686

    Search

    BDNF/NT 3 Growth Factors Receptor-Pipeline Review H2 2017

    BDNF/NT 3 Growth Factors Receptor-Pipeline Review H2 2017

    • Report Code ID: RW0001881480
    • Category Life Sciences
    • No. of Pages 108
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Pipeline Review H2 2017

    Summary

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report BDNFNT 3 Growth Factors Receptor-Pipeline Review H2 2017 outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival proliferation migration differentiation and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding undergoes homodimerization autophosphorylation and activation. The molecules developed by companies in Phase III Phase I Preclinical and Discovery stages are 3 2 6 and 4 respectively. Similarly the universities portfolio in Preclinical stages comprises 4 molecules respectively. Report covers products from therapy areas Central Nervous System Oncology Cardiovascular Metabolic Disorders Ear Nose Throat Disorders Genetic Disorders and Ophthalmology which include indications Alzheimer's Disease Breast Cancer Solid Tumor Bile Duct Cancer (Cholangiocarcinoma) Huntington Disease Neuroendocrine Tumors Non-Small Cell Lung Cancer Pancreatic Cancer Parkinson's Disease Amyotrophic Lateral Sclerosis Brain Cancer Central Nervous System (CNS) Tumor Colorectal Cancer Melanoma Metastatic Colorectal Cancer Neuroblastoma Ovarian Cancer Papillary Thyroid Cancer Post-Traumatic Stress Disorder (PTSD) Rett Syndrome Salivary Gland Cancer Soft Tissue Sarcoma Stroke Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Adrenocortical Carcinoma (Adrenal Cortex Cancer) Anaplastic Large Cell Lymphoma (ALCL) Anxiety Disorders Astrocytoma Biliary Tumor Bladder Cancer Charcot-Marie-Tooth Disease Colon Cancer Depression Diabetic Retinopathy Endometrial Cancer Epilepsy Epithelial Ovarian Cancer Fallopian Tube Cancer Fibrosarcoma Gastrointestinal Stromal Tumor (GIST) Glioblastoma Multiforme (GBM) Head And Neck Cancer Head And Neck Cancer Squamous Cell Carcinoma Hearing Disorders Hepatocellular Carcinoma Ischemic Optic Neuropathy Kidney Cancer (Renal Cell Cancer) Lung Cancer Major Depressive Disorder Metastatic Adenocarcinoma of The Pancreas Metastatic Brain Tumor Metastatic Melanoma Metastatic Renal Cell Carcinoma Multiple Sclerosis Neurology Non-Rhabdomyosarcoma Non-Small Cell Lung Carcinoma Obesity Ocular Melanoma Pain Peritoneal Cancer Pheochromocytoma Phobia Pontine Glioma Prostate Cancer Refractory Acute Myeloid Leukemia Refractory Multiple Myeloma Relapsed Acute Myeloid Leukemia Relapsed Multiple Myeloma Renal Cell Carcinoma Rhabdomyosarcoma Sarcomas Seizures Skin Cancer Tenosynovial Giant Cell Tumor Thyroid Cancer Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Traumatic Brain Injury Ureter Cancer Urethral Cancer and Wilms' Tumor (Nephroblastoma) .

    Furthermore this report also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
    - The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Overview
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Companies Involved in Therapeutics Development
    Addex Therapeutics Ltd
    Array BioPharma Inc
    AstraZeneca Plc
    Boehringer Ingelheim GmbH
    Chronos Therapeutics Ltd
    Daiichi Sankyo Company Ltd
    Exelixis Inc
    Ignyta Inc
    Loxo Oncology Inc
    Plexxikon Inc
    Takeda Pharmaceutical Company Ltd
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Drug Profiles
    Antibodies to Agonize TrKB for Neurology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AR-523-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZ-64-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-7451-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNN-27-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cabozantinib s-malate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CTDP-003-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DS-6051-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    entrectinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    larotrectinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LM-22A4-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LM-22B10-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-7486-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-0131304-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize TrkB Receptor for Central Nervous System Metabolic Disorders and ENT Disorders-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize TrkA and TrkB for Alzheimer's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize TRKB for Neurodegenrative Diseases-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Agonize TrkB for CNS Diseases-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Dormant Products
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Discontinued Products
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)-Product Development Milestones
    Featured News & Press Releases
    Jun 19 2017 Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
    Jun 12 2017 Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Jun 12 2017 Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer
    Jun 03 2017 Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology Annual Meeting
    Jun 03 2017 New Drug Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers
    Jun 01 2017 Ipsen To Present New Data of Cabometyx at ASCO
    May 17 2017 Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 15 2017 Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
    May 12 2017 Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins
    Apr 27 2017 Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions
    Apr 24 2017 Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27 2017
    Apr 05 2017 Loxo Oncology Announces Acceptance of Larotrectinib Oral Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 04 2017 Ignyta Announces New Data on Entrectinib at the 2017 AACR Annual Meeting
    Mar 31 2017 Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017
    Mar 30 2017 Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor Successful Treatment of Glioneuronal Tumor With Pan-TRK CNS-Active Inhibitor Entrectinib Published in Precision Oncology
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indications H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..3) H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..4) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Companies H2 2017 (Contd..3) H2 2017
    Products under Development by Companies H2 2017 (Contd..4) H2 2017
    Products under Development by Companies H2 2017 (Contd..5) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Addex Therapeutics Ltd H2 2017
    Pipeline by Array BioPharma Inc H2 2017
    Pipeline by AstraZeneca Plc H2 2017
    Pipeline by Boehringer Ingelheim GmbH H2 2017
    Pipeline by Chronos Therapeutics Ltd H2 2017
    Pipeline by Daiichi Sankyo Company Ltd H2 2017
    Pipeline by Exelixis Inc H2 2017
    Pipeline by Ignyta Inc H2 2017
    Pipeline by Loxo Oncology Inc H2 2017
    Pipeline by Plexxikon Inc H2 2017
    Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
    Dormant Projects H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Addex Therapeutics Ltd
    Array BioPharma Inc
    AstraZeneca Plc
    Boehringer Ingelheim GmbH
    Chronos Therapeutics Ltd
    Daiichi Sankyo Company Ltd
    Exelixis Inc
    Ignyta Inc
    Loxo Oncology Inc
    Plexxikon Inc
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//bdnf-nt-3-growth-factors-receptor-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//bdnf-nt-3-growth-factors-receptor-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//bdnf-nt-3-growth-factors-receptor-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments